Summary & Overview
HCPCS Level II J9329: Injection of tislelizumab-jsgr, 1 mg
HCPCS Level II code J9329 denotes the injection of tislelizumab-jsgr, reported per 1 mg. As an oncology monoclonal antibody product, this code matters nationally for facility and professional billing in outpatient infusion settings and oncology clinics where immunotherapy treatments are administered. Accurate use of HCPCS Level II code J9329 affects claims processing, clinical documentation alignment, and payer coverage determinations for high-cost biologic therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service settings, typical payer considerations, and the types of benchmarks and policy topics relevant to high-cost infused oncology agents. The publication highlights common modifiers used with HCPCS Level II drug codes, typical sites of service, and where to expect policy variation across major payers. It also outlines how J9329 is reported on service lines and what information is typically required on claims for accurate adjudication.
This summary is written for a national audience and focuses on practical billing and policy aspects of reporting J9329 for tislelizumab-jsgr injection in milligram units.
Billing Code Overview
HCPCS Level II code J9329 represents injection of tislelizumab-jsgr, 1 mg. This code is used to report administration of the specified monoclonal antibody product in a measured milligram unit.
Service Type: Therapeutic infusion/injection of a monoclonal antibody
Typical Site of Service: Hospital outpatient department or physician office infusion/oncology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving intravenous immunotherapy with J9329 (tislelizumab-jsgr, 1 mg) for an FDA‑approved or guideline-supported malignancy (for example, advanced non‑small cell lung cancer or urothelial carcinoma). The patient presents to an outpatient oncology infusion center or hospital outpatient infusion suite for scheduled systemic therapy. Order verification and eligibility are completed at check‑in, baseline vitals and laboratory results are reviewed by the nurse and oncology pharmacist, and the dose is calculated from weight or body surface area and prepared by pharmacy as a sterile injectable product. The infusion nurse performs site verification, confirms premedications if required, and administers the infusion per institutional protocol while monitoring for infusion‑related reactions. Post‑infusion observation and documentation of tolerance, medication lot numbers, and units administered are completed in the electronic health record prior to patient discharge or transfer to oncology clinic follow‑up.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of the single‑use vial is wasted and the discarded amount must be reported for reimbursement tracking (no additional payment). |